stocks logo

RAPP

Rapport Therapeutics Inc
$
16.050
-0.57(-3.430%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.740
Open
16.550
VWAP
16.10
Vol
138.43K
Mkt Cap
585.79M
Low
15.440
Amount
2.23M
EV/EBITDA(TTM)
--
Total Shares
36.50M
EV
300.40M
EV/OCF(TTM)
--
P/S(TTM)
--
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Show More
4 Analyst Rating
up Image
118.07% Upside
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 35.00 USD with a low forecast of 28.00 USD and a high forecast of 42.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
118.07% Upside
Current: 16.050
sliders
Low
28.00
Averages
35.00
High
42.00
JMP Securities
Jason Butler
Buy
Initiates
$28
2025-04-08
Reason
Citizens JMP initiated coverage of Rapport Therapeutics with an Outperform rating and $28 price target. Rapport is developing novel precision therapeutics for central nervous system disorders leveraging receptor-associated proteins for targeted and selective function, the analyst tells investors in a research note. The firm believes this approach can produce clinical candidates differentiated from traditional treatments that target receptors distributed throughout the CNS by driving improved safety/tolerability profiles and broader therapeutic indexes.
Jones Trading
Justin Walsh
Strong Buy
Initiates
$42
2024-10-18
Reason

Valuation Metrics

The current forward P/E ratio for Rapport Therapeutics Inc (RAPP.O) is -4.62, compared to its 5-year average forward P/E of -5.82. For a more detailed relative valuation and DCF analysis to assess Rapport Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.82
Current PE
-4.62
Overvalued PE
-3.44
Undervalued PE
-8.21

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.21
Current EV/EBITDA
-1.93
Overvalued EV/EBITDA
-0.52
Undervalued EV/EBITDA
-5.91

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+58.58%
-27.11M
Operating Profit
FY2025Q1
YoY :
+6.15%
-24.06M
Net Income after Tax
FY2025Q1
YoY :
+6.25%
-0.68
EPS - Diluted
FY2025Q1
YoY :
+9.85%
-20.53M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
293.8K
USD
3
3-6
Months
173.5K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
162.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
436.6K
Volume
1
0-12
Months
69.6K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
1
457.6K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RAPP News & Events

Events Timeline

2025-05-08 (ET)
2025-05-08
07:11:15
Rapport Therapeutics sees cash runway through end of 2026
select
2025-05-08
07:10:50
Rapport Therapeutics reports Q1 EPS (68c) vs. ($11.07) last year
select
2025-03-21 (ET)
2025-03-21
07:02:30
Rapport Therapeutics to present data at 2025 AAN meeting
select
Sign Up For More Events

News

1.0
06-02Newsfilter
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
1.0
05-21Newsfilter
Rapport Therapeutics to Host 2025 Investor and Analyst Day
4.0
05-08NASDAQ.COM
Implied SCHB Analyst Target Price: $25
Sign Up For More News

FAQ

arrow icon

What is Rapport Therapeutics Inc (RAPP) stock price today?

The current price of RAPP is 16.05 USD — it has decreased -3.43 % in the last trading day.

arrow icon

What is Rapport Therapeutics Inc (RAPP)'s business?

arrow icon

What is the price predicton of RAPP Stock?

arrow icon

What is Rapport Therapeutics Inc (RAPP)'s revenue for the last quarter?

arrow icon

What is Rapport Therapeutics Inc (RAPP)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Rapport Therapeutics Inc (RAPP)'s fundamentals?

arrow icon

How many employees does Rapport Therapeutics Inc (RAPP). have?

arrow icon

What is Rapport Therapeutics Inc (RAPP) market cap?